A Phase 2 interventional study of R2R01 and Terlipressin in Hepatorenal Syndrome and Acute Kidney Injury, sponsored by River 2 Renal Corp.. Recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-03.
Sponsored by River 2 Renal Corp. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing terlipressin in Hepatorenal Syndrome — 1 open to participants now, 1 under way, none of them phase 3. Terlipressin · Hepatorenal Syndrome.
Among the 12 studies testing terlipressin in Hepatorenal Syndrome, this one is the 5th largest by planned enrollment, is the only one that started in 2023, is the only one in phase 2, and was the 11th registered.
50 studies on the registry are indexed under Hepatorenal Syndrome; 7 are open to participants now.
Browse Hepatorenal Syndrome studies →1 of the 12 studies testing terlipressin in Hepatorenal Syndrome is open now, in 1 country.
By country, each count listing its studies:
Terlipressin: first FDA approval 2022 (TERLIVAZ). What it is approved for, and how studies give it, is on its page →
Of the 6 Hepatorenal Syndrome studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 4 · Phase 4 2
First in 2002; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 95 is above the median of 50 across 36 interventional studies indexed under Hepatorenal Syndrome.
Median enrollment 65 across the 12 interventional studies. Of the 8 that completed or were terminated, 3 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 12 have an industry lead sponsor. The 8 most frequent:
River 2 Renal Corp. is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
River 2 Renal Corp. has 1 study filed under Hepatorenal Syndrome — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing terlipressin in Hepatorenal Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the safety, tolerability and efficacy of R2R01 combined with terlipressin as compared to terlipressin alone in the treatment of patients with HRS-AKI
This is a phase 2 randomized, single-blind, placebo-controlled, two group, multicenter trial preceded by a safety run-in, in patients with Hepatorenal Syndrome (HRS) - Acute Kidney Injury (HRS-AKI).
The study consists of:
A. an Open-Label Safety Run-In Part with 3 Cohorts of patients, followed by
B. a Single-Blind Placebo-Controlled Randomized Part with two Cohorts of patients treated in parallel, and
C. an Open-Label Terlipressin Non-Responder Cohort.
All patients in all Cohorts will be treated with terlipressin, administered as a slow intravenous (IV) bolus 1 mg over 2 minutes every 6 hours (h) to be increased if clinically appropriate to 2.0 mg every 6 h. Terlipressin dosing should continue up to 24 h after achievement of an HRS response (either Partial or Full) based on Serum Creatinine (SCr)/AKI stage or up to day 14.
For those Cohorts where terlipressin will be administered combined with R2R01 (i.e., Cohorts 1, 2, 3, 4, and 6), the first R2R01 administration will commence immediately following the first terlipressin administration. Like terlipressin treatment, R2R01 dosing should continue up to 24 h after achievement of an HRS response (either Partial or Full) based on SCr/AKI stage or up to day 14.
All patients in all Cohorts will be followed for up to 90 days after the first dose of study drug.
This study will be conducted across approximately 25 centers in EU, UK, US, and Canada.
The screening period will occur within 14 days prior to the first dose administration.
The treatment duration is up to 14 days with a follow-up period of approximately 76 days.
The expected total duration of study participation is up to 15 weeks for each subject.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Three initial cohorts (Cohort 1, N=3 patients, Cohorts 2 and 3, N=6 patients, each) will be treated with an open-label combination of terlipressin and R2R01 to ascertain the safety of the combination therapy. A Safety Review Committee (SRC) will review the safety of Cohort 1 patients based on the adverse events and laboratory abnormalities up until Day 14, prior to the start of recruitment of Cohort 2 patients, as well as the safety of Cohorts 1 and 2 patients up until Day 14 prior to the start of recruitment of Cohort 3 patients. Data from all Cohorts 1, 2, and 3 patients up until Day 14 will be reviewed by the SRC before starting the randomized part of the study (Cohorts 4 and 5), so that the SRC can decide and confirm the most appropriate R2R01 dose schedule for patients in Cohorts 4 and 5. Patients enrolled in Cohorts 1, 2, or 3 will remain in their Cohort until study completion (Day 90) or study discontinuation.
Drug: R2R01 · Drug: Terlipressin
After conclusion of the open-label safety run-in part, and after the SRC has determined the appropriate R2R01 dose schedule, approximately 80 patients will receive terlipressin and be randomized 1:1 to either R2R01 (Cohort 4) or placebo (Cohort 5). At randomization, patients will be stratified by the presence of systemic inflammatory response syndrome (SIRS), since patients with SIRS have shown a better response to terlipressin than patients without SIRS.
Drug: R2R01 · Drug: Terlipressin
In Cohort 5, if patients do not respond to terlipressin, they must discontinue Cohort 5. After discontinuation, they will be allowed to enter Cohort 6 (Terlipressin Non-Responder Part) to receive R2R01 with the same dosing and schedule as that for Cohort 4. No patient from any Cohort other than Cohort 5 will be allowed to enter Cohort 6.
Drug: R2R01 · Drug: Terlipressin
Pharmaceutical form: sterile 2R vials containing 10 mg of R2R01.
In the US, terlipressin is supplied as a sterile, preservative-free, lyophilized, white-to- off-white powder for intravenous (IV) administration. Each vial contains 0.85 mg Terlivaz, equivalent to 1 mg terlipressin acetate, and 10.0 mg mannitol. Terlivaz requires reconstituting in saline (5mL). In the EU, terlipressin is supplied in a clear glass vial with 5 ml of injection solution, containing 1 mg terlipressin acetate corresponding to 0.85 mg terlipressin.
Safety Evaluation Criteria - Treatment Emergent Adverse Events (TEAEs)
Safety and tolerability will be assessed by occurrence of TEAEs. Outcome will be reported as the count of participant experiencing TEAEs.
Time frame: From first dose of study drug to 30 days post last dose
Safety Evaluation Criteria - Change in Weight
Safety and tolerability will be assessed by change in body weight
Time frame: Change from screening through Day 30
Safety Evaluation Criteria - Vital Signs - Respiration Rate
Safety and tolerability will be assessed by change in respiration rate
Time frame: Change from screening through Day 30
Safety Evaluation Criteria - Vital Signs - Body Temperature
Safety and tolerability will be assessed by change in body temperature
Time frame: Change from screening through Day 30
Safety Evaluation Criteria - Vital Signs - Continuous pulse oximetry (SpO2)
Safety and tolerability will be assessed by change in SpO2
Time frame: Change from baseline through Day 30
Safety Evaluation Criteria - Vital Signs - Systolic Blood Pressure (SBP)
Safety and tolerability will be assessed by change in SBP
Time frame: Change from screening through Day 30
Safety Evaluation Criteria - Vital Signs - Diastolic Blood pressure (DBP)
Safety and tolerability will be assessed by change in DBP
Time frame: Change from screening through Day 30
Safety Evaluation Criteria - Vital Signs - Heart Rate (HR)
Safety and tolerability will be assessed by change in Heart Rate (HR)
Time frame: Change from screening through Day 30
Safety Evaluation Criteria - ECGs - PR interval
Safety and tolerability will be assessed by occurrence of ECGs
Time frame: Change from screening to Day 14 or hospital discharge
Safety Evaluation Criteria - ECGs - RR interval
Safety and tolerability will be assessed by occurrence of ECGs
Time frame: Change from screening to Day 14 or hospital discharge
Safety Evaluation Criteria - ECGs - QRS duration
Safety and tolerability will be assessed by occurrence of ECGs
Time frame: Change from screening to Day 14 or hospital discharge
Safety Evaluation Criteria - ECGs - QT interval
Safety and tolerability will be assessed by occurrence of ECGs
Time frame: Change from screening to Day 14 or hospital discharge
Safety Evaluation Criteria - ECGs - QTcF interval
Safety and tolerability will be assessed by occurrence of ECGs
Time frame: Change from screening to Day 14 or hospital discharge
Safety Evaluation Criteria - ECGs - QTcB interval
Safety and tolerability will be assessed by occurrence of ECGs
Time frame: Change from screening to Day 14 or hospital discharge
The incidence of Responders
The incidence of Responders (Established HRS reversal defined as patients with a Full or Partial HRS response (based on SCr/AKI stage) AND are alive without Renal Replacement Therapy (RRT) for at least 30 days after the first dose of study medication), evaluated separately as two different outcome groups and combined. In case of recurrence and retreatment during the first 30 days, the second treatment period will be evaluated for response
Time frame: 90 days
Mortality Rate
Number of patients who died at day 30, 60, and 90.
Time frame: 30, 60, 90 days
Liver Transplant Rates
Number of patients undergoing a liver transplant at day 30, 60, and 90.
Time frame: 30, 60, 90 days
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2023 (actual). Primary completion is estimated for Dec 2024, 18 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Terlipressin
River 2 Renal Corp.